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Human pancreatic growth hormone-releasing factor (GRF-44NH,) stimulated growth hormone (GH) se- 
cretion and intracellular cyclic AMP levels in cultured pituitary cells from both sheep and rat. Somatostatin 
(SRIF), over a wide range of doses and time, showed no significant effect on the elevated cyclic AMP levels 
in sheep cells, but did block the GH release in a dose-dependent manner. In rat cells, however, SRIF inhibit- 
ed GRF-stimulated cyclic AMP levels by 75% maximum (still 8-fold greater than the basal levels) and GH 
release to almost half the basal value. We conclude that somatostatin inhibits GRF-elevated cyclic AMP 
levels in rat pituitary cells but not in sheep cells. 
Growth hormone-releasing factor Growth hormone Somatostatin Cyclic AMP Rat pituitary cell 
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1. INTRODUCTION 
The secretion of growth hormone (GH) by the 
anterior pituitary gland is controlled by at least 
two hypothalamic factors, a stimulatory GH- 
releasing factor (GRF) and an inhibitory factor, 
somatostatin (SRIF). A role of cyclic AMP in the 
control of GH secretion was first suggested by the 
stimulatory effects of inhibitors of cyclic nucleo- 
tide-phosphodiesterase [ 1,2] and cyclic AMP de- 
rivatives [3] on GH release in vitro. Further sup- 
port for the role of this nucleotide in the regulation 
of GH secretion was provided by the inhibitory ef- 
fects of SRIF on cyclic AMP levels as well as on 
GH secretion [4-61. However, other data suggest 
that the primary site of action of SRIF is at a step 
after the elevation of cyclic AMP [7,8]. Recently, 
Abbreviations: GRF, growth hormone-releasing factor; 
SRIF, somatostatin; GH, growth hormone 
peptides with GH-releasing activity have been 
identified [9,10] and shown to stimulate cyclic 
AMP levels in cultured pituitary cells from rat 
[ 11,121 and sheep [ 131. Furthermore, the human 
pancreatic GRF (l-40)-NH2 characterised in [lo] 
has been reported to stimulate adenylate cyclase 
activity in a membrane fraction from rat pituitary 
cells [14]. On the other hand, studies of the action 
of SRIF on GRF-stimulated cyclic AMP levels in 
pituitary cells have produced variable results 
[ll-131. 
Our previous observations howed no significant 
inhibition of GRF-elevated cyclic AMP levels by 
SRIF in sheep pituitary cells [13], whereas in rat 
cells, a 75% inhibition has been reported 111,121. 
To clarify the basis for this difference, which is of 
considerable potential interest for studies of the 
mechanism of action of SRIF, we have in- 
vestigated the effects of SRIF and GRF (44-NH2) 
on both rat and sheep cells in parallel. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Synthetic GRF (44-NHz) and SRIF were ob- 
tained from Universal Biologicals, Cambridge, 
England. Sera and culture media were obtained 
from Gibco Biocult, Paisley, Scotland. Ovine GH 
(NIH-GH-S9,0.56 IU/mg) and rat GH (NIH-GH- 
B6, 1.7 IU/mg) were gifts from Dr A.E. Wilhelmi 
and the National Institute of Arthritis, Diabetes 
and Digestive and Kidney Diseases, NIH, 
Bethesda, MD, USA. 
2.2. Preparation and culture of pituitary cells 
Cells were prepared and incubated according to 
[ 151. Anterior pituitary glands from (4-g-month- 
old) male sheep and (200-250 g) male Sprague- 
Dawley rats were dispersed (90 min, 37°C) using 
collagenase (Boehringer, 1.5 mg/ml), hyaluroni- 
dase (Sigma-type lS, 0.5 mg/ml), deoxyribonucle- 
ase I (Boehringer, grade II, 0.25 mg/ml) and 
bovine serum albumin (Sigma fraction V, 30 
mg/ml) in medium containing NaCl (137 mM), 
KC1 (5 mM), Na2HPOd (0.7 mM), glucose (10 
mM) and Hepes (25 mM), which was adjusted to 
pH 7.4 with NaOH. Cells were collected by centri- 
fugation (400 x g for 2 min) and washed 5 times by 
resuspension in the Hepes-buffered medium and 
centrifugation. Dispersed ovine cells were pipetted 
(0.5-1.0 x lo6 cells/dish) into 3.5 cm culture 
plates (Sterilin), and incubated in Dulbecco’s 
modified Eagle medium (3 ml/dish) containing 
5% foetal calf serum, 10% horse serum and anti- 
biotics for 72 h at 37°C under 95% sir/5% CO2 
[15]. Dispersed rat cells were plated (0.4 x lo6 
cells/well) into Nunclon (6 x 4) multiwell dishes 
(Gibco Biocult) and incubated under the same con- 
ditions as the ovine cells but with only 1.5 ml/well 
culture medium. 
2.3. Experimental incubations 
After 72 h the incubation medium was discarded 
and the cells were washed 3 times with incubation 
medium from which serum was omitted. The cells 
were preincubated for 60 min with serum-free 
medium, and then the medium was replaced and 
experimental incubations were initiated by the ad- 
dition of test substances. At the end of the incuba- 
tion time the media were centrifuged (400 x g, 
2 min) and the supernatants tored at - 20°C until 
assayed for hormone content. The cellular cyclic 
nucleotides were extracted with trichloroacetic acid 
(10% w/v, 2 h at 4’C) and stored frozen at 
-2O”C, prior to extraction and assay. 
2.4. Assays 
The radioimmunoassay procedures for both 
ovine GH and rat GH were based on previous 
methods [ 151. Hormones were iodinated with 
Na”‘I by the iodogen method in [ 161. All samples, 
standards, etc. were dissolved in assay buffer con- 
taining sodium phosphate (0.05 M), pH 7.6, mer- 
thiolate (0.6 mM), bovine serum albumin (O.OS~o), 
and Triton X-100 (0.05%). Cellular cyclic AMP 
samples were acetylated and measured according 
to [17]. 
2.5. Treatment of results 
All experiments were performed at least twice 
with different preparations of pituitary cells and 
consistent results were obtained. In each case the 
results of a representative xperiment have been 
presented. Control and experimental values were 
compared for statistically significant differences 
using Student’s t-test. 
3. RESULTS 
3.1. Time course of the effect of GRF on GH 
secretion and its inhibition by SRIF: sheep 
pituitary cells 
The stimulation of GH secretion from sheep 
pituitary cells by 1 nM GRF (fig. 1) was significant 
at the earliest ime tested, 2 min (80% stimulation, 
p < 0.001). The maximum stimulation of GH 
release lasted for 5 min, after which a lower (but 
still elevated) secretion rate for GH was main- 
tained throughout the time course. By 30 min total 
GH secretion was 4-5-fold greater than basal (and 
maximum stimulation of secretion rate was con- 
siderably greater than this; fig.1). SRIF (0.5 PM) 
completely blocked this stimulation during the first 
15 min, and after 30 min incubation SRIF had in- 
hibited GRF-elevated GH secretion to below the 
basal secretion rate. 
3.2. Time course of the effect of GRF on cellular 
cyclic AMP levels and its inhibition by 
somatostatin in sheep pituitary cells 
GRF (1 nM) stimulated cellular cyclic AMP 
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Fig. 1. Time course of the effect of GRF on GH secretion 
in the absence or presence of SRIF (top) and cellular 
cyclic AMP levels (bottom). Sheep pituitary cells were 
cultured for 3 days and then treated with 1 nM GRF 
(0). 1 nM GRF plus 0.5 ,uM SRIF (0) or no additions 
(0). For each time point the values for hormones 
released and cyclic AMP content represent the mean 
values f SE per IO6 cells, obtained from 4 replicate 
dishes. The appropriate control and experimental values 
were compared for statistically significant differences by 
Student’s t-test. Probability values: Ir, p < 0.001; ns, 
not significant. 
levels 5-fold within 2 min (fig.1). A maximal 
lo-fold elevation was apparent by 5 min (fig.l), 
and after 15 min the elevated cyclic AMP levels 
declined somewhat. SRIF had no significant effect 
on the time course. 
3.3. Dose dependence of the effect of SRIF on the 
GRF-stimulated GH secretion and cellular 
cyclic AMP levels in sheep pituitary cells 
The effects of various SRIF concentrations on 
GRF (0.1 nM)-stimulated GH secretion and 
cellular cyclic AMP levels after 30 min are shown 
in fig.2. GH secretion (open circles) was stimulated 
2-fold, and SRIF inhibited this effect of GRF in a 
dose-dependent manner. Inhibition to below basal 
level was produced by 0.1 PM SRIF. On the other 
hand, over the dose range tested, SRIF had no 
significant effect on the 4-fold elevated cyclic 
AMP levels (closed circles) (fig.2). At higher SRIF 
concentrations (0.5 PM) we have occasionally 
noticed a (150-200%) stimulation of cellular cyclic 
AMP levels above that seen with GRF alone. 
SRI,= CONCENTRATIONS (nM) 
Fig.2. Dose-response relationships for the action of 
SRIF on GRF-stimulated GH secretion (0) and cyclic 
AMP content (0) in cultured sheep pituitary cells. For 
all observations except the controls 0.1 nM GRF was 
present, with the concentration of SRIF shown. For each 
treatment the values for GH released and cyclic AMP 
content represent he mean value + SE per lo6 cells, 
from 4 replicate dishes. 
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3.4. Dose dependence of the effect of SRIF on 
GRF-stimulated GH secretion and cellular 
cyclic AMP levels in rat pituitary cells 
The results with rat pituitary cells are shown in 
fig.3. GH secretion was only stimulated 70% by 
1 nM GRF after 30 min (open circles), though 
cellular cyclic AMP levels were elevated 32-fold 
(closed circles). An inhibition of the effects of 
GRF on both GH secretion and cyclic AMP levels 
was observed with SRIF, the dose-dependence 
curves apparently being parallel. A maximally ef- 
fective dose of SRIF (1 nM) inhibited GH secre- 
tion to almost half the basal secretion value, 
whereas cellular cyclic AMP levels still remained 
&fold higher than the basal content. 
4. DISCUSSION 
Our data clearly show that SRIF does not inhibit 
the rapid GRF stimulation of cyclic AMP concen- 
trations in sheep pituitary cells, ~though the pep- 
tide produces a rapid and potent inhibition of 
GRF-stimulated GH secretion. This indicates that 
the major site of action of SRIF in regulating GH 
secretion in these cells probably lies beyond cyclic 
AMP production. These findings accord with our 
earlier work with GRF 1131, and with 
isobutylmethylxanthine and SRIF [ 181 using sheep 
pituitary cells, and also with the work of authors 
in [7] using bovine pituitary cells. They do not 
agree with previous studies using rat pituitary cells, 
which suggested that SRIF could inhibit the 
stimulation of adenylate cyclase caused by GRF 
[l 1,19,20]. Our results, presented here, clarify this 
situation. SRIF does indeed lower GRF-stimulated 
cyclic AMP levels in rat pituitary cells and an im- 
portant species difference exists between rat and 
sheep cultured pituitary cells. 
In these studies, which have used heterogeneous 
cell populations, it must be recognised that the 
non-somatotroph cell populations could be mask- 
ing changes in cellular cyclic AMP levels in the 
sheep somatotrophs. However, this seems unlikely 
because although the magnitude of the difference 
observed between rat and sheep anterior pituitary 
cell preparations was very marked, somatotrophs 
constitute a similar and large (30-40%) proportion 
of the cells present. Further, since effects of GRF 
appear to be highly specific for GH secretion [9], 
changes in cyclic AMP levels induced by this factor 
should represent primarily changes occurring in 
the somatotroph. 
Our results are consistent with the hypothesis 
that SRIF exerts its inhibitory effects on at least 
two sites in the rat pituitary ceils [11,20]; one of 
these is at adenylate cyclase whilst the other is as 
yet undefined but is independent of cyclic AMP 
concentrations. In sheep cells the second site would 
appear to predominate. Modulation of cellular 
processes controlling Ca2+-dependent stimulus- 
secretion coupling may be an alternative site for in- 
hibitory regulation by SRIF [ll]. Rat somato- 
trophs may display functional heterogeneity 
[21,22] and inhibition of adenylate cyclase by SRIF 
may operate predominantly in one subpopulation 
of the cells. 
Authors in [ 191, using rat pituitary cells, showed 
that pertussis toxin (which inactivates the Ni in- 
hibitory protein of adenylate cyclase by ADP 
ribosylation f23]) could block the inhibition by 
SRIF of both GRF-induced GH release and 
0 
0 
g 
t 
CONTROLS 0 ” 0.1 1.0 10 100 
SRIF CONCENTRATIONS (nkl) 
Fig.3. Dose-response relationships for SRIF acting on 
GRF-stimulated GH secretion (0) and cyclic AMP 
content (0) in cuhured rat pituitary cells. For all 
observations except the controls 1.0 nM GRF was 
present, with the concentration of SRIF shown. For each 
treatment the values for GH released and cyclic AMP 
content represent he mean value k SE per 0.4 x lo6 
cells, from 4 replicate dishes. Probability value: Q , p < 
0.01. 
15 
Volume 179, number 1 FEBS LETTERS January 1985 
cellular cyclic AMP accumulation, which suggests 
that the inhibition of adenylate cyclase by SRIF is 
associated with its effects on GH secretion in the 
rat. However, our results and those in [ 11,201 show 
that SRIF-attenuated cyclic AMP concentrations 
in GRF-treated rat cells were still approx. g-fold 
greater than the basal values, suggesting that in- 
hibition of GRF-stimulated adenylate cyclase by 
SRIF may not entirely explain its effects on GH 
secretion, even in the rat. 
It is noteworthy that the inhibitory potency of 
SRIF on GH secretion measured in the rat 
pituitary cell cultures (fig.3) was much greater than 
that observed in experiments with the sheep 
pituitary cells (fig.2). It is possible that in the rat 
cells the inhibition by SRIF of adenylate cyclase 
may potentiate its effects on other mechanisms in- 
volved in the inhibitory control of secretion. 
In conclusion, the results presented here suggest 
that the lowering of cyclic AMP levels plays little 
role in the inhibition by SRIF of GRF-stimulated 
secretion of sheep GH. Lowering of cyclic AMP 
levels may play such a role in the rat, but its impor- 
tance is not yet established. 
ACKNOWLEDGEMENTS 
We thank Pfizer Central Research Ltd. and the 
SERC for support, Tony Ricketts for advice and 
encouragement, and Mrs Eileen Willis for typing 
the manuscript. 
REFERENCES 
VI 
121 
131 
141 
Schofield, J.G. (1967) Biochem. J. 103, 331-341. 
Wilber, J.F., Peake, G.T., Mariz, I., Utiger, R.F. 
and Daughaday, W.H. (1968) Clin. Res. 16, 
277-280. 
Labrie, F., BCraud, G., Gauthier, M. and Lemay, 
A. (1971) J. Biol. Chem. 246, _1902-1908. 
Borgeat, P., Ladrie, F., Drouin, J., BClanger, A., 
Immer, H., Sestanj, K., Nelson, V., Gotz, M., 
Schally, A.V., Coy, D.H. and Coy, E.J. (1974) 
Biochem. Biophys. Res. Commun. 56, 1052-1059. 
[51 
161 
[71 
PI 
PI 
WI 
1111 
WI 
1131 
1141 
1151 
1161 
v71 
ml 
WY 
Lw 
WI 
L=l 
P31 
Belanger, A., Labrie, F., Borgeat, P., Savary, M., 
Cote, J., Drouin, J., Schally, A.V., Coy, D.H., 
Coy, E.J., Immer, H., Sestanj, K., Nelson, V. and 
Gotz, M. (1974) Mol. Cell Endocrinol. 1, 329-339. 
Kaneko, T., Oka, H., Saito, S., Munemura, M., 
Masa, K., Oda, T., Yanaihara, N. and Yanaihara, 
C. (1973) Endocrinol. Jap. 20, 535-538. 
Bicknell, R.J. and Schofield, J.G. (1981) Mol. Cell 
Endocrinol. 22, 85-94. 
Sheppard, M.S., Spence, J.W. and Kraicer, J. 
(1979) Endocrinology 105, 261-268. 
Guillemin, R., Brazeau, P., BCihlen, P., Esch, F., 
Ling, N. and Wehrenberg, W.B. (1982) Science 
218, 585-587. 
Rivier, J., Spiess, J., Thorner, M. and Vale, W. 
(1982) Nature 300, 276-278. 
Bilezikjian, L.M. and Vale, W.W. (1983) 
Endocrinology 113, 1726-1731. 
Michel, D., Lefkvre, G. and Labrie, F. (1983) Mol. 
Cell Endocrinol. 33, 255-264. 
Law, G. J., Ray, K.P. and Wallis, M. (1984) FEBS 
Lett. 166, 189-193. 
Labrie, F., Gagne, B. and Lef*vre, G. (1983) Life 
Sci. 33, 2229-2233. 
Ray, K.P. and Wallis, M. (1982) Mol. Cell 
Endocrinol. 27, 139-155. 
Fraker, P.J. and Speck, J.C. (1978) Biochem. Bio- 
phys. Res. Commun. 80, 849-857. 
Brooker, G., Harper, J.F., Terasaki, W.L. and 
Moylan, R.P. (1979) Adv. Cyclic Nucleotide Res. 
10, l-33. 
Law, G.J., Ray, K.P. and Wallis, M. (1983) 
Abstracts, 2nd Joint Meeting of British Endocrine 
Societies, p.53. 
Cronin, M.J., Rogol, A.D., Myers, G.A. and 
Hewlett, E.L. (1983) Endocrinology 113, 209-215. 
Harwood, J.P., Grewe, C. and Aguilera, G. (1984) 
Mol. Cell Endocrinol. 37, 277-284. 
Snyder, G., Hymer, W.C. and Snyder, J. (1977) 
Endocrinology 101, 788-799. 
Hall, M., Howell, S.L., Schulster, D. and Wallis, 
M. (1982) J. Endocrinol. 94, 
Hildebrandt, J.D., Sekura, 
Iyengar, R., Manclark, C.R. 
(1983) Nature 302, 706-709. 
257-266. 
R.D., Codina, J., 
and Birnbaumer, L. 
16 
